In a significant development for public health, the U.S. Food and Drug Administration (FDA) has expanded the approved age indication for GSK’s Arexvy (Respiratory Syncytial Virus vaccine, adjuvanted) to include adults aged 18 to 49 years who are at increased risk for lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). Previously, Arexvy was approved for individuals aged 60 and older, as well as those aged 50 to 59 with certain risk factors.
This expansion is particularly relevant given that an estimated 21 million adults under the age of 50 in the United States have at least one risk factor for severe RSV infection. Sanjay Gurunathan, GSK’s Head of Vaccines and Infectious Diseases Research and Development, stated that this age expansion addresses a crucial medical need for those at higher risk of severe RSV disease due to underlying health conditions. He emphasized the goal of easing the burden on the healthcare system while broadening access to RSV prevention.
Each year, the impact of RSV among adults aged 18 to 49 results in approximately 17,000 hospitalizations, 277,000 emergency department visits, and nearly 2 million outpatient visits. Most hospitalizations within this younger demographic occur among those with chronic medical conditions such as chronic cardiopulmonary diseases, obesity, and diabetes.
Clinical Evidence Supporting the Approval
The FDA’s decision to expand the age indication for Arexvy was supported by data from a Phase IIIb trial (NCT06389487), which demonstrated a non-inferior immune response in the younger population compared to adults aged 60 and above. Previous Phase III trials (NCT04886596) have also confirmed the vaccine’s efficacy.
The safety profile of Arexvy aligns with findings from earlier studies that supported the initial approval. Common adverse events reported include injection site pain, fatigue, myalgia, headache, and arthralgia, usually occurring within four days post-vaccination. GSK aims to continue advancing regulatory submissions for Arexvy in various regions to expand its availability and support long-term growth objectives.
About Arexvy and RSV
Arexvy utilizes recombinant RSV glycoprotein F stabilized in its prefusion conformation (RSVPreF3) combined with GSK’s proprietary AS01E adjuvant. This vaccine is not intended for leverage in pregnant individuals and should be administered according to official recommendations. Notably, while vaccines can elicit a protective immune response, it may not occur in all individuals.
Globally, RSV is a highly contagious virus impacting an estimated 64 million people annually across all age groups. Adults may be at increased risk for severe RSV due to comorbidities, immune status, or age. RSV can exacerbate underlying conditions, leading to severe outcomes such as pneumonia, hospitalization, and even death. Compared to children, adults hospitalized for RSV face higher risks of severe complications, necessitating more costly treatments and revealing a higher fatality rate. Many RSV-related cases are likely underestimated due to the lack of routine testing.
Next Steps and Implications
The approval of Arexvy for younger adults marks a critical step forward in addressing the burden of RSV in the United States. GSK’s commitment to expanding access to this vaccine is expected to alleviate pressure on healthcare systems while improving health outcomes for at-risk populations. As the vaccine becomes available to a broader audience, monitoring its uptake and effectiveness will be essential in assessing its impact on public health.
For more information on Arexvy, including dosage, administration, and safety details, refer to the full U.S. Prescribing Information. As developments continue, GSK remains focused on further expanding the vaccine’s availability across multiple geographies.
Engagement with healthcare providers and public health officials will be crucial in promoting awareness and uptake of this vital vaccine. Comments and shares on this topic are encouraged to foster discussion and information dissemination.
Disclaimer: This article provides information for educational purposes and does not constitute medical advice. For personalized health concerns, consult a healthcare professional.
